United Therapeutics has been closely monitoring the rapidly evolving situation around Coronavirus (COVID-19). We are dedicated to providing ongoing support for patients and healthcare providers, and ensuring an uninterrupted supply of drug product.

Remodulin Co-pay Assistance Program

The Remodulin Co-Pay Assistance Program, offered through United Therapeutics, allows most eligible patients who enroll to pay as little as a $5 co-pay for each prescription—up to $8000 savings per year.

How do my patients enroll in this program?

Your patients must be 18 years or older and understand and agree to comply with the eligibility requirements and terms of use.

Patients are eligible for this program if they:

  • Have commercial (also known as private) insurance and are taking the medication for an FDA-approved indication
  • Are residents of the US or Puerto Rico

Patients utilizing Medicare, Medicaid, or any other state or federal government program to pay for their medications are not eligible. Patients who start utilizing government coverage during the term of the program will no longer be eligible.

The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program. Void where prohibited, taxed, or restricted by law.

Find more details about the Co-Pay Assistance Program at www.UTcopay.com

Support through United Therapeutics ASSIST®

Access Solutions and Support Team, a United Therapeutics resource for patients prescribed Remodulin

ASSIST, the Access Solutions and Support Team, is a United Therapeutics resource committed to helping your patients access their prescribed Remodulin. Patients can also learn more about possible financial support options available to them.

Once your patients start Remodulin treatment, an ASSIST advisor will work with you, your patients, and the Specialty Pharmacy to help them understand their insurance coverage, answer questions, and discuss financial assistance options.

Reach out to an ASSIST advisor at 1-877-864-8437 Monday-Friday 8:30 am to 7:00 pm ET.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).